Related Experiment Video
Updated: Jun 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Results from recent therapeutic trials in hypertension]
1Hôpital Européen Georges-Pompidou, service de médecine vasculaire et hypertension artérielle, 75908 Paris Cedex 15. guillaume.bobrie@egp.aphp.fr
Abstract:
The decrease in systolic/diastolic blood pressure of 100/50 mmHg obtained by antihypertensive therapy is associated with a 22% reduction of coronary events and 41% of cerebrovascular events. The benefit is independent of initial blood pressure level without threshold effect. The benefit is linked to lower blood pressure itself. The doctrine of comparable effectiveness of all antihypertensive drugs is challenged by more recent works. Although patients at high cardiovascular risk in clinical trials included are treated better than before, receiving as many other preventive treatments (statins, aspirin), it seems to remain a high residual cardiovascular risk that seems incompressible.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Hypertension II: Pathophysiology